Prokaryotic expression, purification, and reconstitution of biological activities (antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2

Biochemical and Biophysical Research Communications

Volumn 276, Issue 3, 2000, Pages 1286-1294

  Rao, C N ^a   Reddy, Prasad ^b   Reeder, Dennis J ^b   Liu, Yueying ^a   Stack, Sharon M ^a   Kisiel, W ^c   Woodley, David T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Antitumor activity; Extracellutar matrix; Glycosylation; Heparin; Kunitz type serine protease inhibitors; Prokaryotic expression; Protein refolding; Recombinant TFPI 2

Indexed keywords

HEPARIN; PLACENTA PROTEIN 5; PLASMIN; PROTEINASE INHIBITOR; SERINE PROTEINASE; TISSUE FACTOR PATHWAY INHIBITOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; GLYCOSYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; START CODON; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 0034610074     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.3611     Document Type: Article

References (31)

1. Molecular cloning, expression, and partial characterization of a second tissue factor pathway inhibitor
2. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor-2
3. cDNA cloning and mRNA expression of a serine protease inhibitor secreted by cancer cells: Identification as placental 5 and tissue factor pathway inhibitor-2
4. Extracellular matrix-associated serine protease inhibitors (M(r) 33,000, 31,000, and 27,000) are single gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2
5. Partial characterization of matrix-associated serine protease inhibitors from human skin cells
6. Novel extracellular matrix-associated serine protease inhibitors from human skin fibroblasts
7. Partial characterization of novel serine protease inhibitors from human umbilical vein endothelial cells
8. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2
9. Hyperexpression and purification of Escherichia coli adenylate cyclase using a vector designed for expression of lethal gene products
10. The degradation signal in a short lived protein
11. In vivo significance of kinetic constants of protein proteinase inhibitors
12. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor
13. Variants of the cell recognition site of fibronectin that retain cell attachment-promoting activity
14. Matrix-localization of tissue factor pathway inhibitor-2 matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: Heparin accelerates the activity of TFPI-2/MSPI towards plasmin
15. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
16. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications
17. Regulation of coagulation by multivalent Kunitz-type inhibitor
18. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli
19. Regulation of proMMP-1 and proMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor
20. Biology and biochemistry of proteinases in tumor invasion
21. Activation of pro-urokinase and plasminogen on sarcoma cells
22. Plasminogen activation by tPA on the surface of human melanoma cells in the presence of alpha2-macroglobulin secretion
23. Metastatic behavior of human melanoma cells in nude mice correlates with urokinase type plasminogen activator, its type 1 inhibitor, and urokinase mediated degradation
24. Binding and activation of plasminogen at the surface of human keratinocytes
25. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases
26. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
27. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
28. Treatment with soy-bean derived Bowman-Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice
29. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
30. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428
31. Synthetic inhibitor of matrix metalloproteinases decreases tumor growth and metastasis in a syngenic model of rat prostate cancer in vivo